Korro Bio reports Q2 EPS ($2.43), consensus ($2.39)

“We continue to advance KRRO-110, our lead candidate for the treatment of AATD, and remain on track to submit a regulatory filing in the second half of 2024. This is only possible with the team’s focus, and support of our manufacturing partners,” said Dr. Ram Aiyar, CEO and President of Korro. “We believe KRRO-110 has the potential to be transformative for patients with AATD, as evidenced by the robust body of preclinical data across multiple animal models. Supported by the $70.0 million private placement completed in April 2024, we remain focused on executing on multiple value-creating milestones and bringing a new therapeutic modality forward.”